Multiparameter Optimization of <i> <i>Pseudomonas aeruginosa</i> </i> Elastase Inhibitors for Systemic Administration
Targeting the extracellular protease elastase (LasB) of the high-priority pathogen <i><i>Pseudomonas aeruginosa</i></i> is a promising strategy to develop second-generation, narrow-spectrum antibiotics with a novel mode of action. <i><i>P. aeruginosa</i></i> is responsible for a variety of infections, particularly of the lung. Herein, we report the structure-based optimization of a previously reported potent and selective phosphonate-based LasB inhibitor scaffold. Having improved the activity while maintaining high selectivity and favorable ADMET properties, we also demonstrate, for the first time within this scaffold, that intravenous administration leads to favorable lung retention. We could rationally align this with <i>in vitro</i> plasma protein binding. We further observed a link between physicochemical properties like logD<sub>7.4</sub> and protein binding, including surfactant proteins that can impair compound activity in the lung. This multiparameter optimization paves the way for the exploration of additional indications requiring systemic treatment, such as hospital-acquired or ventilator-associated pneumonia.
Authors
- Katharina Mundry
- Ahmed S. Abdelsamie (ORCID: https://orcid.org/0000-0002-5326-4400)
- Dominik Kolling (ORCID: https://orcid.org/0009-0005-1365-3128)
- Brigitta Loretz (ORCID: https://orcid.org/0000-0003-0057-5181)
- Katharina Rox (ORCID: https://orcid.org/0000-0002-8020-1384)
- Jelena Konstantinović (ORCID: https://orcid.org/0000-0002-2572-8538)
- Christian Schütz (ORCID: https://orcid.org/0000-0002-2455-3123)
- Yu Mi Park (ORCID: https://orcid.org/0000-0003-1864-486X)
- Anna K. H. Hirsch (ORCID: https://orcid.org/0000-0001-8734-4663)
- Mélodie Bouté
- Jesko Koehnke (ORCID: https://orcid.org/0000-0002-7153-1365)
- Richard Müller
- Roya Shafiei (ORCID: https://orcid.org/0000-0001-9783-595X)
- Samira Speicher
- Jean-Michel Sallenave
- Jörg Haupenthal
- Andreas M. Kany
- Claus-Michael Lehr
- Andreas Klein
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Chembio (United States) (US)
- Bioscience Research (US)
- German Center for Infection Research (DE)
- Helmholtz Centre for Infection Research (DE)
- Helmholtz Center for Information Security (DE)
- Centre de Recherche sur l'Inflammation (FR)
- Helmholtz Institute for Pharmaceutical Research Saarland (DE)
- Hôpital Bichat-Claude-Bernard (FR)
- Physiopathologie et Epidémiologie des Maladies Respiratoires (FR)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1021/acs.jmedchem.5c02788
- Primary Topic
- Microbial Natural Products and Biosynthesis
- Type
- article
- Field-Weighted Citation Impact
- 0.00